REG - Indivior PLC - Appointment of Independent Non-Executive Director

IndiviorAnnouncement

09/11/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231109:nRSI8638Sa&default-theme=true

RNS Number : 8638S  Indivior PLC  09 November 2023

Indivior PLC - Appointment of Independent Non-Executive Director

 

Slough, UK and Richmond, VA, November 9, 2023 - Indivior PLC (LSE/NASDAQ:
INDV) announces the appointment of Keith Humphreys, OBE, PhD, as an
Independent Non-Executive Director of the Company with immediate effect. Dr.
Humphreys has also been appointed as a member of the Compliance, Ethics &
Sustainability, Nomination and Science Committees.

 

Dr. Humphreys is an Esther Ting Memorial Professor in the Department of
Psychiatry and Behavioral Sciences at Stanford University.  He was previously
a Senior Policy Advisor in the White House Office of National Drug Control
Policy in the Obama Administration and is an Honorary Professor of Psychiatry
at the Institute of Psychiatry, King's College, London.  Dr. Humphreys was
awarded an OBE in September 2022 for his services to science and policy on
addiction.

 

Dr. Tom McLellan will continue to serve as a Non-Executive Director to support
a smooth transition and will step down from the Board with effect from
February 29, 2024.

 

Graham Hetherington, Chair, commented:

 

'We are pleased to have Keith join Indivior's Board as an Independent
Non-Executive Director. With over 30 years of experience in the field of
clinical psychology and substance use disorders, Dr. Humphreys is one of the
leading minds in the substance abuse space and his research addresses
addictive disorders and translation of science into public policy. He will be
a tremendous asset as we continue to focus on our purpose of bringing
science-based, life-transforming treatments to patients.'

 

'On behalf of the Board, I would like to take this opportunity to thank Tom
for his significant contribution and commitment to Indivior over the last nine
years, and appreciate his dedication to the furtherance of our and the
public's understanding of the substance use disorder disease space.'

 

There is no further information to disclose in relation to Keith Humphreys'
appointment in accordance with Listing Rule 9.6.13.

 

This announcement is made in accordance with Listing Rule 9.6.11.

 

 

 

About Indivior

Indivior is a global pharmaceutical company working to help change patients'
lives by developing medicines to treat addiction and serious mental illnesses.
Our vision is that all patients around the world will have access to
evidence-based treatment for the chronic conditions and co-occurring disorders
of substance use disorder (SUD). Indivior is dedicated to transforming SUD
from a global human crisis to a recognized and treated chronic disease.
Building on its global portfolio of OUD treatments, Indivior has a pipeline of
product candidates designed to both expand on its heritage in this category
and potentially address other chronic conditions and co-occurring disorders of
SUD, including alcohol use disorder and cannabis use disorder. Headquartered
in the United States in Richmond, VA, Indivior employs more than 1,000
individuals globally and its portfolio of products is available in 37
countries worldwide. Visit www.indivior.com to learn more. Connect with
Indivior on LinkedIn by visiting www.linkedin.com/company/indivior.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUWUAROBUARUA